Volitionrx Ltd
VNRX NYSE· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 23, 2026
$0.17
KIRA · Stoqly’s AI analyst, in plain words
- Volitionrx Ltd had $1.7M of revenue in fiscal 2025, up 40.0% on the year before. Over five years, revenue changed +164.3% a year on average.
- Its operating margin was −1,258.5%, up 932.5 pts: of every 100 in sales, about −1,258 is left after running the business.
- Volitionrx Ltd lost $23.4M in fiscal 2025.
- Free cash flow was −$19.8M in fiscal 2025, −1,144.7% of revenue.
- Volitionrx Ltd owes $5.6M more than it holds in cash.
Market cap
$1.6M
P/E
—
Revenue
$1.7M
Net income
−$23.4M
Free cash flow
−$19.8M
Operating margin
−1,258.5%
Volitionrx Ltd in 30 seconds · fiscal 2025
Are sales growing?
+40.0%
Yes. Sales grew 40.0% last year.
Does it make a profit?
−1,352.1%
No. It lost money last year.
Does profit turn into cash?
−1,144.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
What Volitionrx Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- VOLITIONRX LTD
- CIK
- 0000093314
Volitionrx Ltd · VNRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.3M | $0.8M | $1.2M | $1.7M |
| Revenue growth | 571.6% | 240.4% | 153.0% | 59.1% | 40.0% |
| Operating margin | −31,481.2% | −10,372.1% | −4,641.8% | −2,190.9% | −1,258.5% |
| Net income | −$27.0M | −$30.6M | −$35.7M | −$27.0M | −$23.4M |
| Net margin | −29,988.7% | −9,986.5% | −4,601.7% | −2,186.3% | −1,352.1% |
| Diluted EPS | −$0.51 | — | −$0.50 | −$0.31 | — |
| Cash | |||||
| Cash from operations | −$20.9M | −$15.3M | −$18.1M | −$25.9M | −$19.7M |
| Capital expenditure | $1.0M | $1.6M | $1.1M | $0.3M | $0.1M |
| Free cash flow | −$21.8M | −$16.8M | −$19.1M | −$26.2M | −$19.8M |
| FCF margin | −24,252.8% | −5,498.7% | −2,469.6% | −2,121.7% | −1,144.7% |
| Share buybacks | — | $0.0M | $0.0M | $0.0M | — |
| Share count change | 16.3% | — | — | 21.5% | 23.5% |
| Debt and strength | |||||
| Cash and short-term investments | $20.6M | $10.9M | $20.7M | $3.3M | $1.1M |
| Debt incl. finance leases | $3.1M | $3.8M | $4.8M | $4.8M | $6.7M |
| Shareholders' equity | $17.7M | −$2.6M | −$7.8M | −$24.9M | −$34.2M |
| Current ratio | 3.4x | 0.7x | 2.4x | 0.5x | 0.2x |
| Interest coverage | −181.9x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | −10,689.2% | — | — | — | — |
| Return on equity | −158.7% | −404.0% | — | — | — |
| Return on tangible equity | −154.2% | — | — | — | — |
| Piotroski F-score | 4 | 2 | 5 | 2 | 2 |
| Altman Z'' | −17.6 | −43.5 | −29.5 | −102.3 | −151.1 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Volitionrx Ltd · VNRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.17 a share, the company is worth $1.6M.
Source: SEC EDGAR XBRL filings (CIK 0000093314). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.